Next Article in Journal
Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics
Previous Article in Journal
Supramolecular Motifs in the Crystal Structures of Triethylbenzene Derivatives Bearing Pyridinium Subunits in Combination with Pyrimidinyl or Pyridinyl Groups
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 18
10.3390/molecules28186484
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Ultrasound Sonosensitizers for Tumor Sonodynamic Therapy and Imaging: A New Direction with Clinical Translation

by
Yunlong Liang
1,
Mingzhen Zhang
2,
Yujie Zhang
2,* and
Mingxin Zhang
3,*
1
Second Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang 712046, China
2
School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an 710061, China
3
Department of Gastroenterology, The First Affiliated Hospital of Xi’an Medical University, Xi’an 710077, China
*
Authors to whom correspondence should be addressed.
Molecules 2023, 28(18), 6484; https://doi.org/10.3390/molecules28186484
Submission received: 24 July 2023 / Revised: 25 August 2023 / Accepted: 31 August 2023 / Published: 7 September 2023
(This article belongs to the Special Issue Discovery and Development of Targeted Anticancer Nanomedicines)
Browse Figures
Versions Notes

Abstract

:
With the rapid development of sonodynamic therapy (SDT), sonosensitizers have evolved from traditional treatments to comprehensive diagnostics and therapies. Sonosensitizers play a crucial role in the integration of ultrasound imaging (USI), X-ray computed tomography (CT), and magnetic resonance imaging (MRI) diagnostics while also playing a therapeutic role. This review was based on recent articles on multifunctional sonosensitizers that were used in SDT for the treatment of cancer and have the potential for clinical USI, CT, and MRI applications. Next, some of the shortcomings of the clinical examination and the results of sonosensitizers in animal imaging were described. Finally, this paper attempted to inform the future development of sonosensitizers in the field of integrative diagnostics and therapeutics and to point out current problems and prospects for their application.

1. Introduction

Despite enormous efforts to cure cancer, it is still the most serious health problem human beings face in the 21st century due to its high morbidity and mortality [1]. Presently, there are four primary approaches that have received approval for the clinical management of cancer: surgery, chemotherapy, radiotherapy, and immunotherapy [2]. However, these treatments are also associated with high recurrence rates and uncontrollable adverse effects. Therefore, what is the future of anti-cancer therapy with high efficiency and low medical costs? Recently, several non-invasive cancer treatment modalities have attracted the attention of researchers worldwide, among which photothermal therapy (PTT), photodynamic therapy (PDT), and sonodynamic therapy (SDT) are representative methods [3,4,5]. PTT induces necrosis or decomposition of cancerous tissue by activating the energy converted through the photothermal agents (PTAs) [3,4,5]. PTT converts the absorbed light energy into heat energy by activating photothermal agents (PTAs) to induce necrosis or disintegration of cancer tissue. Although PTT has been recognized for its efficacy in the treatment of cancer since the 19th century, it is poorly targeted to cancer patients due to photothermal agents (PTAs). PTT may cause unnecessary medical harm by causing damage to healthy tissues unrelated to treatment [6,7]. Both PDT and SDT are considered high-precision and non-invasive treatment modalities. PDT is a treatment based on the conversion of light energy absorbed by photosensitizer molecules into reactive oxygen species (ROS), thereby mediating tumor cell death. However, since light can only penetrate a few millimeters of tumor tissue, PDT is only suitable for some superficial tumors.
As the research progresses, the benefits of SDT in the treatment of tumors have attracted our strong interest. SDT is a non-invasive treatment that does not require incisions or punctures, reducing surgical risks and recovery time. SDT can maximize the protection of surrounding healthy tissue by adjusting the energy and depth of focus of ultrasound. Compared with radiation therapy or chemotherapy, SDT treatment does not produce radiation, reducing the damage to surrounding normal tissues. Depending on the patient, SDT allows for individualized treatment plans to be designed to improve outcomes. Because SDT has so many advantages, its use in oncology has been widely studied. The research and development were simultaneously able to treat and provide imaging guidance, providing valuable direction for multimodal therapeutic applications of cancer treatment [8].
This paper began with a comprehensive summary of the mechanics of SDT. Next, it will focus on sonosensitizers with clinical translation potential and integrated diagnostic and therapeutic capabilities. Finally, the clinical application of diagnostic and therapeutic integrated sonosensitizers, as well as the future development direction, were prospected.

2. Overview of SDT

The origins of SDT can be traced back to the evolution of PDT. PDT is a technology that uses the photodynamic effect produced by photosensitizers for disease diagnosis and treatment. The process is that light at a specific wavelength (600–800 nm) activates a photosensitizer in the target tissue, which in turn transmits the received energy to oxygen molecules in an excited state in the tissue, thereby inducing the generation of ROS. Singlet oxygen (1O2), hydrogen peroxide (H2O2), and hydroxyl radicals (·OH) are the main components of ROS. Reactive oxygen species produce cytotoxic effects, leading to cell damage and even death [9,10]. SDT shares similarities in mechanism with PDT, but it uses acoustic energy rather than light energy. SDT has several advantages over PDT. The penetration depth of ultrasound into biological tissues is much deeper than that of light [11]. Therefore, SDT can be used to treat deep tumors, such as those in the liver, brain, and pancreas [12,13]. In addition, the cavitation effect of ultrasound can cause mechanical damage to cells, and ultrasound can also change the fluidity of the phospholipid bilayer, thereby changing the membrane permeability [14]. Besides, the acoustic force has lower operating and instrument costs. Furthermore, since visible light can activate most of the photosensitizing chemicals used in PDT therapy, patients may experience photosensitizing allergic reactions after the use of photosensitizers that may affect the quality of their survival [15]. It is generally accepted that SDT is a method of producing cytotoxic effects by means of acoustic sensitizers with very low biotoxicity [16]. Therefore, SDT is a more promising tumor treatment strategy than PDT.
SDT, as a non-intrusive means, can kill cancer cells precisely by controlling the intensity, frequency, and time of ultrasound irradiation to activate the sonosensitizers accumulated at the tumor site. The cytotoxic effects of SDT were first reported in 1989, when researchers observed that the combination of US and the photosensitizer hematoporphyrin produced cytotoxic effects on mouse sarcoma cells [17]. Subsequently, the phenomenon of hematoporphyrin producing cytotoxic effects under ultrasonic irradiation was named the “sonodynamic method” [18]. In recent years, various types of sonosensitizers, including porphyrins, phthalocyanines, chlorines, and a variety of acoustic nanomaterials, have been discovered that can generate ROS and exert cytotoxic effects triggered by US irradiation [19,20]. The toxic effects of SDT on tumor cells can be achieved by activating apoptosis and immunity and affecting the tumor microenvironment. Studies have shown that the generated ROS in SDT treatment caused a decrease in mitochondrial membrane potential, which led to damage to mitochondria, and then cytochrome c (Cyt c) was released from the mitochondria into the cytoplasm, and finally the caspase-dependent apoptotic pathway was activated [21,22]. Honda et al. [23] reported that disrupted mitochondrial membrane potential released ROS, which further activated Caspase-3 and ultimately led to the induction of DNA breaks. The growth and metastasis of cancer cells depend on the tumor microenvironment. Over the past few years, several studies have revealed that the tumor microenvironment is regulated by multiple factors, including SDT treatment. Gao et al. [24] found that SDT can induce ROS production in the tumor microenvironment, which can significantly inhibit the proliferation, migration, and invasion of endothelial cells. In addition, SDT can activate immune responses via SDT-injured tumor debris or immune response complexes in the tumor microenvironment. The results showed that M2 macrophages in the tumor were converted to the M1 phenotype during SDT treatment. Meanwhile, dendritic cells (DCs) in the tumor microenvironment tended to mature as the expression levels of CD80 and CD86 molecules increased in activated T cells [25]. SDT treatment promotes the proliferation of cytotoxic T-lymphocytes (CD8+ T-cells) in tumors by upregulating the expression of CRT, HMGB1, and HSP70 [26].

3. Mechanisms of SDT

Thermal and non-thermal effects may be the main pathways through which SDT works [16]. Figure 1 depicts the principle of SDT operation.

3.1. Thermal Damage

When tissues are irradiated by ultrasound, some of the energy carried by the sound waves is converted into heat energy. If the temperature of the tissue exceeds the threshold (56 °C), it becomes thermotoxic, leading to irreversible coagulative necrosis of the cells. It has been developed as a strategy to focus high-energy ultrasound on the lesion for the thermal ablation of tumors [27]. High-intensity focused ultrasound (HIFU) has been used in clinical disease since the latter half of the 1990s and achieves thermal coagulation in less than 12 s. In clinical practice, HIFU treatment uses conventional frequencies ranging from 0.8 to 3.5 MHz. High-frequency ultrasound between these frequencies carries a higher energy beam than diagnostic ultrasound. At lower deposition energy doses (<55 °C), the induced hyperthermia increases the cell permeability to facilitate nanoparticle delivery effectively [28]. This is advantageous when used in conjunction with thermally modulated carrier molecules. At higher doses of deposition energy (>55 °C), cells die due to coagulative necrosis [29].

3.2. Non-Thermal Effects

The non-thermal effects of ultrasound can be categorized as follows: (i) ultrasonic cavitation effect; (ii) generation of ROS; and (iii) ultrasound-induced apoptosis of cancer cells.

3.2.1. Ultrasonic Cavitation Effect

When intense ultrasound waves irradiate tissue fluid, much of the microbubbles are produced and collapse, a process known as cavitation, which contains inertial cavitation and non-inertial cavitation in general [30,31]. The inertial cavitation process includes the stages of nucleation, expansion, oscillation, and implosive collapse of microbubbles in liquids, which process generates localized extremely high temperatures (>10,000 K) and pressures (>81 MPa) as well as free radicals [32]. Non-inertial cavitation, sometimes called “stable cavitation,” is a sustained linear or nonlinear oscillation around the equilibrium radius of an acoustically driven bubble [33]. Stable cavitation leads to microflows characterized by the generation of fluid flow [28]. However, microfluidics can lead to cell lysis and death [34]. Also, the stable cavitation generates heat due to the loss of viscosity at the bubble surface boundary. As these extreme physical conditions dramatically alter the environmental balance within the tissue, irreversible damage to cellular structures is induced, ultimately leading to cellular necrosis.

3.2.2. Generation of Reactive Oxygen Species

The production of ROS, including singlet oxygen (1O2), hydroxyl radicals (OH), peroxides, and superoxide (O2−), is the main source of cytotoxicity in SDT. It has been suggested that the interaction of ultrasound with different types of sonosensitizers to produce ROS may involve acoustic cavitation, acoustoluminescence, and pyrolysis [2]. Although different types of cavitation effects produce mechanical effects, acoustic-chemical species are only produced by inertial cavitation [35]. Inertial cavitation is an ultra-violent process of nanometer bubble activity at a microsecond level, usually accompanied by extremely high temperature (>10,000 K) and pressure, which leads to the pyrolysis of water vapor within the microbubble, generating highly reactive hydroxyl radicals and hydrogen atoms [35]. It was reported that when receiving ultrasonic energy, nanobubbles can behave as cores for inertial cavitation, thereby inducing ROS production [36]. After receiving acoustic energy from ultrasonic cavitation, the sonosensitizers are mobilized from the basal state to the exciting mode, and then the activated sonosensitizers return to the basal state, releasing energy and reacting directly with the surrounding oxygen to produce single-linear oxygen [35]. As the cavitation bubble expands and eventually collapses, a transient hot spot of high temperature and high pressure is formed, generating self-luminescence light from ultraviolet (UV) to visible light, called sonoluminescence. Studies have shown that some sonosensitizers with photosensitizing properties are able to absorb and convert the light generated during ultrasonic cavitation into heat and reactive oxygen species [37]. The sonosensitizers were activated by sonoluminescence and finally transferred electrons to O2, generating cytotoxic ROS, which can induce membrane lipid peroxidation, cell membrane instability, and irreversible cellular damage [38,39]. However, for some sonosensitizers that lack photosensitivity, ROS cannot be generated via the acoustoluminescent pathway. Kessel et al. [40] showed that ultrasound-mediated inertial cavitation of microbubbles on the liquid surface at high localized temperatures induced the decomposition of ultrasound sensitizers. The widely accepted theory suggests that ROS generated during inertial cavitation can be directly pyrolyzed or chemically reacted with sonosensitizers to generate free radicals, which further react with other endogenous substances to generate more ROS [41].

4. Integration of Diagnosis and Treatment

Therapeutics refers to treatment strategies that combine diagnostic tests with specific treatments based on test results, a term derived from “diagnosis” and “treatment” [42]. This capability to integrate imaging and therapy is critical for the future treatment of cancer. As a result, sonosensitizers have recently received extensive research in the field of cancer diagnosis and treatment [43]. In recent years, with the development of novel nanoparticles (NPs), some multifunctional sonosensitizers can not only treat tumors but also play the function of imaging, including MRI, USI, CT, photoacoustic imaging (PAI), and fluorescence imaging (FLI), realizing the integration of cancer diagnosis and therapy [44,45,46,47,48,49,50] (Figure 2). In cancer diagnostics, many multifunctional sonosensitizers can be used as contrast agents (CA) for imaging examinations, which is easily achieved due to their targeted nature and specific enrichment in tumor tissues [51,52]. Compared with conventional scanning techniques, nanoparticle-based contrast agent micrography features noninvasive, instant monitoring, targeting, and high spatial and temporal resolution, which provides a basis for accurate diagnosis and visual tracking during healing. In tumor therapy, sonosensitizers as imaging contrast agents play a role in treating tumors while visually tracking their accumulation in tumor tissue with the help of their imaging capabilities. Comparison of the gray-scale changes of tumor tissues and their quantitative gray-scale values in the imaging maps of the imaging instruments (CT, US, and MRI) before and after SDT treatment allows a visual and easy assessment of the treatment effect [8,48]. In addition, the use of ultrasound bio-imaging capabilities and continuous tracking of drug retention time in the tumor allows for accurate and timely information during treatment, thus improving the accuracy of SDT and the optimal duration of treatment after i.v. administration. Therefore, combining these sonosensitizers with clinical examination can effectively improve the accuracy of image information and facilitate clinical analysis and treatment. This review focuses on three imaging modalities (MRI, USI, and CT) mediated by sonosensitizers and their basic principles, aiming at a better understanding of sonosensitizers for imaging and therapeutic use and looking ahead to the challenges of clinical translation.

5. Sonosensitizers with Various Imaging Functions

5.1. Contrast-Enhanced Ultrasound (CEUS)

Ultrasound (US) is a sound wave with a frequency of more than 20,000 Hz that is inaudible to the human ear. Ultrasound has the advantages of low-cost, simple, rapid, non-invasive, non-radioactive, accurate, continuous, dynamic, and repeatable scans [43,56,57]. Using the physical properties of ultrasound, various cross-sectional images of organs and surrounding organs can be displayed, which is close to the anatomical real structure. Therefore, ultrasound is often used as the first choice for the examination of solid organs and fluid-containing organs. In particular, ultrasound elastography and contrast-enhanced ultrasound (CEUS) are well established as being used for diagnosis. In CEUS, intravenously injected microbubbles are excited by longitudinal ultrasound in the examined area, producing nonlinear oscillations. The corresponding contrast agent software can distinguish the diseased tissues from the received contrast agent signals [58]. However, currently, 78.5% of radiology departments use diagnostic ultrasound imaging as a routine diagnostic imaging method, while only 26% of them use contrast-enhanced ultrasound [58]. The excessively expensive price of ultrasound contrast agents and their lower selectivity limited the clinical application of CEUS. It was found that some sonosensitizers used for SDT treatment also showed promising results in CEUS. Table 1 lists the sonosensitizers and imaging capabilities used for CEUS imaging. Sonosensitizers produce stable microbubbles (MBs) or nanobubbles (NBs) under CEUS cavitation to achieve enhanced imaging [59,60,61]. Sonosensitizers achieve synergistic drug delivery and tumor therapy by affecting the lesion’s tissue structure. Therefore, with the development of sonosensitizers, the clinical application of contrast-enhanced ultrasound is becoming more and more broad.
Chen M. et al. [49] reported a liposomal nanoparticle based on porphyrin/camptothecin-floxuridine triad microbubbles (PCF-MBs). The novel PCF-MB not only realized ultrasound imaging but also achieved chemo-photodynamic combination therapy. After intravenously injecting 1 mg/mL of PCF-MBs into Balb/c nude mice bearing HT-29 colon cancer, the ability of PCF-MBs to potentiate ultrasound imaging was investigated by a fixed-frequency ultrasound transducer. The results showed that before the injection, there was hardly any sonographic signal in the tumor. The ultrasound imaging signals peaked 20 s after injection, and the peak state lasted more than 3 min (Figure 3A).
Zhang et al. [66] synthesized a composite system in which Mn-doped In2S3/InOOH (SMISO) is loaded in spinodal silica (r-SiO2) to integrate ultrasound imaging and SDT for the detection and treatment of breast cancer. The live Type B US imaging results showed that the grayscale was changed after injection of SiO2, MISO, or SMISO solutions in the 4T1 breast tumor model, and there was a statistical difference between SMISO and the control group (p < 0.01), suggesting SMISO could achieve ultrasound imaging (Figure 3B,C). Further, it was found that the signal intensity increased after SMISO NPs injection and peaked at 12 h, guiding the optimal time for ultrasound irradiation. And then, 12 h after the NPs injection, the signal intensity gradually decreased until it disappeared, indicating that the NPs were eliminated from the tumor. Under US irradiation, the SMISO NPs effectively inhibited tumor growth. In summary, the nanoplatform simultaneously had therapeutic efficacy and imaging capability.
Zhang L et al. [47] fabricated an innovative nanoplatform capable of multimodal (FLI/PAI/USI) imaging using IR780 and perfluoropentane (PFP), as well as guiding SDT for tumor treatment. After intravenous injection of IR780-NDs, researchers acquired enhanced ultrasound images of xenograft tumors in nude mice with 4T1 breast cancer. At 24 h after administration in the caudal i.v., the US signal in CEUS mode showed brightness (Figure 3D). In addition, the quantification data indicated that the echo intensity was much stronger in the post-injection group than in the pre-injection group.
Ho et al. [45] designed multi-functional superhydrophobic mesoporous silica nanoparticles (FMSNs) for the encapsulation of the clinical anti-cancer drug Doxorubicin (FMSNs-Dox). In this study, monodisperse silica super-hydrophobicity was utilized to significantly improve the contrast of ultrasound images by enhancing the accumulation of interfacial nanobubbles (INBs). FMSNs-Dox possessed excellent ultrasound imaging ability, an anti-vascular effect, and antitumor treatment capability under ultrasound irradiation. US images showed that the contrast was significantly enhanced by INBs in tumor tissue from 1–9 days.

5.2. X-ray Computed Tomography (CT)

CT scanning utilizes a computer to process a combination of several X-ray images acquired from different angulations to develop an anatomical picture of the scanned object [73]. CT has become a popular noninvasive clinical imaging method because of its reproducibility, low price, and ease of use [74]. CT scans are divided into conventional and enhanced scans according to whether contrast media is used or not. Since plain CT cannot distinguish between tissues with similar mass attenuation coefficients (e.g., normal organs and tumors), exogenous X-ray attenuating CT contrast materials need to be injected intravenously to identify diseased tissues. Iodine contrast is commonly used in clinical practice but has the following limitations: (1) susceptibility to allergic reactions and nephrotoxicity; (2) low dose-efficiency ratio; and (3) lack of targeting. Studies have investigated the utilization of sonosensitizers as CT imaging agents to overcome the shortcomings of commonly used clinical contrast agents. Table 2 lists the sonosensitizers and imaging capabilities used for CT imaging.
Cao et al. [51] designed and synthesized titanium oxide (TiO2) nanosheets with triphenylphosphine (TPP) and AS1411 aptamer structure to realize mitochondria-targeted, CT imaging, and sonodynamic-chemotherapy for cancer treatment (Figure 4A). Relative to the control group, Au-TiO2-A-TPP-treated mice displayed significant CT signals at the tumor sites, which validated the capability of Au-TiO2-A-TPP to diagnose tumors by CT imaging in vivo (Figure 4B). As the concentration of Au-TiO2-A-TPP increased, the brightness and CT values of CT images increased, suggesting a linear relationship between CT grayscale values and concentration (Figure 4C). As mentioned previously, contrast agents commonly used in clinical practice may not be appropriate for patients with renal insufficiency, who may be better suited for contrast agents with a short half-life in vivo and low nephrotoxicity. Surprisingly, the half-life of Au-TiO2-A-TPP in the blood circulation of mice was only 4.71 h, indicating Au-TiO2-A-TPP was very promising for patients with renal insufficiency (Figure 4D).
Cheng K et al. [48] developed an AgBiS2@DSPE-PEG2000-FA (ABS-FA) with good biosafety and active targeted CT imaging capability that combined photothermal and ultrasound kinetic treatment capabilities. It was found that ABS-FA had significant targeting in tumor tissues in vivo, and the CT signals at the site of the tumor were steadily enhanced after ABS-FA (300 μL, 5 mg/mL) injection, reaching a peak at 6–12 h. However, the non-targeted ABS-NH2 signals did not change at different time points at the tumor site (Figure 4E). The results of low-power (0.35 W/cm2) infrared thermography were consistent with those of CT, which showed that the thermal signal appeared 2 h after drug injection and reached its maximum 10 h after injection (Figure 4F).
Zhang et al. [75] constructed a novel oral nanoparticle, Au@mSiO2/Ce6/DOX/SLB-FA@CMC (GMCDS-FA@CMC), that endowed the pH/ultrasonic dual-response to realize the combination of SDT with chemotherapy for colorectal cancer treatment. After oral delivery of GMCDS-FA@CMC, a well-defined tumor CT signal was observed in situ in colorectal cancer model mice and persisted for 7–9 h. It was found that the enteric-coated particles possessed good CT imaging effects in vivo by oral delivery and could be used to direct SDT-chemotherapy for colorectal cancer treatment.

5.3. Magnetic Resonance Imaging (MRI)

Since the first implementation of MRI in 1973 as a non-invasive and multi-contrast detection method, MR imaging has been widely used in various biomedical fields [76]. MRI can reflect tissue lesions by combining parameters such as flow effects and electromagnetic wave-related proton density after the excitation of strong magnetic field pulses and the formation of magnetic resonance phenomena through hydrogen atoms in human water molecules [77]. The images are also processed with the aid of computer technology to obtain an excellent diagnosis of the pathology, which has high spatial and tissue resolution [78,79,80]. Therefore, it is extensively utilized clinically in the diagnosis and prognostic status of various diseases. Magnetic resonance imaging is not sensitive, but this obstacle can be overcome by exogenous contrast agents by decreasing the relaxation time of bulk water [80,81]. It was found that appropriate contrast agents are important for enhancing the susceptibility and specificity of diagnosis, enhancing the degree of signal contrast, and improving the resolution of soft tissue images for clinical application [76]. For example, with the help of gadolinium (Gd)-based T1 agents, information about the boundaries of brain tumors can be observed more clearly [82]. In recent years, some new nuclear magnetic sensitizers containing Mn and Fe have been applied to MRI tumor imaging [83,84]. Table 3 lists the sonosensitizers and imaging capabilities used for MRI imaging.
Lei et al. [83] recommended iron-doped vanadium disulfide nanosheets (Fe-VS2 NSs) as novel sonosensitizers modified with polyethylene glycol (PEG) to achieve the combination of SDT with chemodynamic therapy (CDT) for cancer therapy. Fe-VS2-PEG NSs have magnetic resonance imaging capability and strong tumor inhibility in vivo. At 24 h after intravenous administration of Fe-VS2-PEG, MR imaging of the tumor demonstrated significant enhancement, and the quantitative analysis showed that signal strength was 2.04 times stronger than that before administration. (Figure 5B,C). In addition, the concentration of Fe-VS2-PEG NSs was positively correlated with MR signal intensity (Figure 5D).
Wang et al. [84] designed and constructed Janus nanostructures called UPFB, consisting of upconversion nanoparticles (UCNPs) (NaYF4:20%Yb, 1%Tm@NaYF4:10% Yb@NaNdF4) and porphyrin-based metal organic frameworks (MOFs) (PCN-224(Fe)). UPFB promoted ROS production by GSH depletion and oxygen supply and realized the integration of SDT and chemodynamic therapy (CDT) for oncology treatment under MRI guidance. Compared with the UPF group, the UPFB group darkened overtime at the tumor site, indicating that the T2 contrast signal was enhanced and the accumulation of UPFB was in a time-related manner (Figure 5E). UPFB was highly enriched in tumor tissues by quantitative analysis of the biodistribution of Zr and Fe elements by inductively coupled plasma mass spectrometry (ICP-MS) Figure 5F,G). Furthermore, the circulation half-life of UPFB was calculated to be 3.381 h (Figure 5H). All these results suggested that the UPFB possessed excellent tumor target ability and could be utilized as a contrast agent for T2-weighted.
Guan et al. [91] reported a novel biodegradable nanomaterial derived from a mesoporous zeolitic-imidazolate framework@MnO2/doxorubicin hydrochloride (ZIF-90@MnO2/DOX, mZMD NCs) to achieve T1-weighted MRI-guided SDT/CDT/chemotherapy. It was found that the MR image brightness increased with the concentration of mZMD NCs (Figure 5I). After 8 h of intravenous administration, the tumor region was significantly brighter for imaging, indicating that mZMD NCs can effectively aggregate at the tumor site and release Mn2+ for T1-weighted MR imaging. The mZMD NCs showed good biocompatibility and biosafety and effectively suppressed the growth of tumor cells.

5.4. Multi-Modal Imaging

All imaging methods have their disadvantages: MRI has the characteristics of long acquisition time and low space coverage; CT has the risk of ionizing radiation; and the US has limited penetration ability [92,93,94,95]. Single-modality imaging cannot meet the growing demand for accuracy and reliability in clinical diagnostics or clinical research [96]. The combined application of multiple testing techniques has become a hot research topic, complementing each other’s advantages and realizing more precise diseases [97]. Compared with single-mode imaging, multimode imaging achieves multiple imaging functions through a single nanomaterial, providing a basis for accurate cancer diagnosis [98]. To date, several nanoparticle-based bimodal co-imaging materials have been reported to achieve better imaging and treatment.
Wang et al. [99] prepared hollow CoP@N-carbon@PEG (CPCs@PEG) nanospheres (∼60 nm) as sonosensitizers to inhibit tumor growth by promoting ROS production under US irradiation. With the incorporation of cobalt ions, which had magnetic properties and X-ray attenuation coefficients, CPCs@PEG were capable of both CT and MRI. Further, the authors also performed MRI imaging studies in vivo using 4T1 tumor-bearing mice as a model. After the injection of CPC10@PEG, the contrast of the cancer site became darker. In addition, the researchers conducted a CT imaging capability study. With the increase in CPC10@PEG concentration, the CT signal was gradually enhanced. The researchers also investigated the in vivo CT imaging capabilities of CPC10@PEG, which showed a significant increase in the brightness of the cancer site after intravenous injection compared with pre-injection.
Gong et al. [44] designed and prepared a novel high-performance multifunctional sonosensitizer built on ultramicroscopic oxygen-deficient bimetallic oxide MnWOX nanoparticles for multimodal imaging-guided SDT for cancer therapy. The MnWOX-PEG nanoparticles exhibited effective SDT effects by producing 1O2 and ·OH and possessed the glutathione depletion capability to enhance the SDT efficacy. MnWOX-PEG exhibited good biosafety and excellent tumor growth suppression in mice under ultrasound irradiation. Due to the high attenuation of X-rays by the W element, MnWOX-PEG can also be applied in CT imaging and as a reduction agent for T1 in magnetic resonance imaging. The findings indicated that after 24 h of intravenous injection of MnWOX-PEG 4T1, the tumor-bearing mice showed significant CT (2.4 times) and MRI (1.8 times) signals in the tumor site. These multimodal imaging results demonstrated that MnWOX-PEG can efficiently accumulate in tumors, and sonosensitizers had diagnostic imaging capabilities and assisted in the precise treatment of tumors with SDT.

6. Conclusions and Outlook

This review summarized the mechanism of action of SDT and further described the advantages and disadvantages of the three molecular imaging modalities commonly practiced in clinical practice, as well as summarized studies using sonosensitizers as contrast agents. SDT has the advantages of a good therapeutic effect, profound organization penetration, and small collateral damage, which makes it a promising cancer treatment. There have been efforts to use SDT for the treatment of cancer and the production of related sonosensitizers since its discovery in 1989. Now, the door seems to have been opened to the great value of sonosensitizers for imaging in addition to cancer treatment, which is becoming an attractive trend. Clinical imaging techniques contribute to earlier and more predictable detection of cancer, provide an accurate and effective evaluation of tumor treatment, and help patients improve their prognosis and survival. However, the limitations of current clinical contrast agents are taken into account. Therefore, it is particularly important to create sonosensitizers with better diagnostic contrast capabilities.
First, although current research on sonosensitizers is in full swing, most of them are facing different problems. Feng et al. [8] developed a sequential strategy for ultrasound-mediated nano-therapy based on TPZ/HMTNPs-SNO. When encountered with ultrasound, TPZ/HMTNPs-SNO further sensitizes the release of nitric oxide (NO) bubbles for ultrasound cancer imaging in a controlled manner. However, when compared with clinical ultrasound contrast agents (Albunex, Echovist, etc.), the ultrasound imaging performance of HMTNPs-SNO is not satisfactory due to the limited NO concentration. Although research on sonosensitizers is in full swing, it still faces great challenges, such as low sensitization efficiency, a lack of accumulation in lesion areas, and insufficient research on therapy mechanisms. To overcome these restrictions, cross-disciplinary collaboration shall be strengthened to construct functionalized sonosensitizers with highly productive diagnostic and therapeutic methods.
Second, the biosafety assessment of sonosensitizers is a central barrier to promoting clinical translation. However, the phototoxicity of organic sonosensitizers and the composition of inorganic sonosensitizers greatly limit their clinical translation. Most of the sonosensitizers currently used for CT and MRI contain heavy metals (e.g., manganese and titanium) whose metabolism, biodegradation, bioavailability, and toxicity in humans are unknown. Therefore, we still need to explore sonosensitizers that are less toxic or even non-toxic to humans. Meanwhile, a comprehensive and systematic evaluation of their toxicity and pharmacology is needed to promote the development of sonosensitizers.
Third, from a clinical perspective, many factors remain to be considered to maximize the imaging quality of sonosensitizers. The identification and validation of novel imaging targets must be attended to, and other features must be investigated in the context of the need for clinical application. We hypothesized that we could contribute to the scientific community’s great progress in cancer imaging and therapy by highlighting the latest achievements in this field. The future development of sonosensitizers for SDT will provide valuable information and insights to facilitate the clinical translation of sonosensitizers for SDT for therapeutic and diagnostic purposes. Based on the research advances in this study, these nanoparticles for imaging and therapeutic versatility will hopefully provide new expectations for clinical applications in cancer therapy.

Author Contributions

Conceptualization, Y.L., M.Z. (Mingzhen Zhang) and Y.Z.; methodology, Y.Z.; writing—original draft preparation, Y.L., M.Z. (Mingzhen Zhang) and Y.Z.; writing—review and editing, Y.L., M.Z. (Mingzhen Zhang) and Y.Z.; supervision, M.Z. (Mingzhen Zhang); project administration, M.Z. (Mingxin Zhang). All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (No 82000523), and the National Science Foundation of Shaanxi (No. 2023-JC-QN-0817).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are not available from the authors.

Abbreviations

SDT, Sonodynamic therapy; USI, Ultrasound imaging; CT, X-ray computed tomography; MRI, Magnetic resonance imaging; PTT, Photothermal therapy; PDT, Photodynamic therapy; PTAs, Photothermal agents; ROS Reactive oxygen species; O2−, Superoxides; H2O2, Hydrogen peroxide; ·OH, Hydroxyl radicals; Cyt c, Cytochrome c; DCs, Dendritic cells; HIFU, High-intensity focused US; UV, Ultraviolet; NPs, Nanoparticles; PAI, Photoacoustic imaging; FLI, Fluorescence imaging; CA, Contrast agents; US, Ultrasound; CEUS, Contrast-enhanced ultrasound; nIR, near infra-red; MBs, Microbubbles; NBs, Nanobubbles; PFP, Perfluoropentane; INBs, Interfacial nanobubbles; PCF-MBs, Porphyrin/camptothecin-floxuridine triad microbubbles; TiO2, Titanium oxide; TPP, Triphenylphosphine; MOFs, Metal organic frameworks; CDT, Chemodynamic therapy; NO, Nitric oxide; ICP-MS, Inductively coupled plasma mass spectrometry.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
  2. Wu, N.; Fan, C.H.; Yeh, C.K. Ultrasound-activated nanomaterials for sonodynamic cancer theranostics. Drug Discov. Today 2022, 27, 1590–1603. [Google Scholar] [CrossRef] [PubMed]
  3. Pan, X.; Wang, H.; Wang, S.; Sun, X.; Wang, L.; Wang, W.; Shen, H.; Liu, H. Sonodynamic therapy (SDT): A novel strategy for cancer nanotheranostics. Sci. China Life Sci. 2018, 61, 415–426. [Google Scholar] [CrossRef]
  4. Gordon Spratt, E.A.; Gorcey, L.V.; Soter, N.A.; Brauer, J.A. Phototherapy, photodynamic therapy and photophoresis in the treatment of connective-tissue diseases: A review. Br. J. Dermatol. 2015, 173, 19–30. [Google Scholar] [CrossRef]
  5. Yu, J.; Chu, C.; Wu, Y.; Liu, G.; Li, W. The phototherapy toward corneal neovascularization elimination: An efficient, selective and safe strategy. Chin. Chem. Lett. 2021, 32, 99–101. [Google Scholar] [CrossRef]
  6. Zhao, L.; Zhang, X.; Wang, X.; Guan, X.; Zhang, W.; Ma, J. Recent advances in selective photothermal therapy of tumor. J. Nanobiotechnol. 2021, 19, 335. [Google Scholar] [CrossRef]
  7. Shang, T.; Yu, X.; Han, S.; Yang, B. Nanomedicine-based tumor photothermal therapy synergized immunotherapy. Biomater. Sci. 2020, 8, 5241–5259. [Google Scholar] [CrossRef] [PubMed]
  8. Feng, Q.; Zhang, W.; Yang, X.; Li, Y.; Hao, Y.; Zhang, H.; Hou, L.; Zhang, Z. pH/Ultrasound Dual-Responsive Gas Generator for Ultrasound Imaging-Guided Therapeutic Inertial Cavitation and Sonodynamic Therapy. Adv. Healthc. Mater. 2018, 7, 1700957. [Google Scholar] [CrossRef] [PubMed]
  9. Czarnecka-Czapczyńska, M.; Aebisher, D.; Oleś, P.; Sosna, B.; Krupka-Olek, M.; Dynarowicz, K.; Latos, W.; Cieślar, G.; Kawczyk-Krupka, A. The role of photodynamic therapy in breast cancer—A review of in vitro research. Biomed. Pharmacother. Biomed. Pharmacother. 2021, 144, 112342. [Google Scholar] [CrossRef]
  10. Liao, S.; Cai, M.; Zhu, R.; Fu, T.; Du, Y.; Kong, J.; Zhang, Y.; Qu, C.; Dong, X.; Ni, J.; et al. Antitumor Effect of Photodynamic Therapy/Sonodynamic Therapy/Sono-Photodynamic Therapy of Chlorin e6 and Other Applications. Mol. Pharm. 2023, 20, 875–885. [Google Scholar] [CrossRef]
  11. Yang, Y.; Huang, J.; Liu, M.; Qiu, Y.; Chen, Q.; Zhao, T.; Xiao, Z.; Yang, Y.; Jiang, Y.; Huang, Q.; et al. Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy. Adv. Sci. 2023, 10, e2204365. [Google Scholar] [CrossRef] [PubMed]
  12. Zha, B.; Yang, J.; Dang, Q.; Li, P.; Shi, S.; Wu, J.; Cui, H.; Huangfu, L.; Li, Y.; Yang, D.; et al. A phase I clinical trial of sonodynamic therapy combined with temozolomide in the treatment of recurrent glioblastoma. J. Neuro-Oncol. 2023, 162, 317–326. [Google Scholar] [CrossRef]
  13. Huang, S.; Ding, D.; Lan, T.; He, G.; Ren, J.; Liang, R.; Zhong, H.; Chen, G.; Lu, X.; Shuai, X.; et al. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis. Acta Biomater. 2023, 164, 538–552. [Google Scholar] [CrossRef]
  14. Brault, D. Physical chemistry of porphyrins and their interactions with membranes: The importance of pH. J. Photochem. Photobiol. B Biol. 1990, 6, 79–86. [Google Scholar] [CrossRef] [PubMed]
  15. Vrouenraets, M.B.; Visser, G.W.; Snow, G.B.; van Dongen, G.A. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res. 2003, 23, 505–522. [Google Scholar]
  16. Sofuni, A.; Itoi, T. Current status and future perspective of sonodynamic therapy for cancer. J. Med. Ultrason. 2022. [Google Scholar] [CrossRef]
  17. Yumita, N.; Nishigaki, R.; Umemura, K.; Umemura, S. Hematoporphyrin as a sensitizer of cell-damaging effect of ultrasound. Jpn. J. Cancer Res. Gann 1989, 80, 219–222. [Google Scholar] [CrossRef]
  18. Umemura, S.; Kawabata, K.; Yurnita, N.; Nishigaki, R.; Umemura, K. Sonodynamic approach to tumor treatment. In Proceedings of the IEEE 1992 Ultrasonics Symposium Proceedings, Tucson, AZ, USA, 20–23 October 1992; Volume 2, pp. 1231–1240. [Google Scholar] [CrossRef]
  19. Li, D.; Yang, Y.; Li, D.; Pan, J.; Chu, C.; Liu, G. Organic Sonosensitizers for Sonodynamic Therapy: From Small Molecules and Nanoparticles toward Clinical Development. Small 2021, 17, e2101976. [Google Scholar] [CrossRef]
  20. Hong, L.; Pliss, A.M.; Zhan, Y.; Zheng, W.; Xia, J.; Liu, L.; Qu, J.; Prasad, P.N. Perfluoropolyether Nanoemulsion Encapsulating Chlorin e6 for Sonodynamic and Photodynamic Therapy of Hypoxic Tumor. Nanomaterials 2020, 10, 2058. [Google Scholar] [CrossRef]
  21. Yumita, N.; Iwase, Y.; Nishi, K.; Ikeda, T.; Komatsu, H.; Fukai, T.; Onodera, K.; Nishi, H.; Takeda, K.; Umemura, S.; et al. Sonodynamically-induced antitumor effect of mono-l-aspartyl chlorin e6 (NPe6). Anticancer Res. 2011, 31, 501–506. [Google Scholar] [PubMed]
  22. Wan, G.Y.; Liu, Y.; Chen, B.W.; Liu, Y.Y.; Wang, Y.S.; Zhang, N. Recent advances of sonodynamic therapy in cancer treatment. Cancer Biol. Med. 2016, 13, 325–338. [Google Scholar] [CrossRef]
  23. Honda, H.; Kondo, T.; Zhao, Q.L.; Feril, L.B., Jr.; Kitagawa, H. Role of intracellular calcium ions and reactive oxygen species in apoptosis induced by ultrasound. Ultrasound Med. Biol. 2004, 30, 683–692. [Google Scholar] [CrossRef] [PubMed]
  24. Gao, Z.; Zheng, J.; Yang, B.; Wang, Z.; Fan, H.; Lv, Y.; Li, H.; Jia, L.; Cao, W. Sonodynamic therapy inhibits angiogenesis and tumor growth in a xenograft mouse model. Cancer Lett. 2013, 335, 93–99. [Google Scholar] [CrossRef] [PubMed]
  25. Wang, S.; Hu, Z.; Wang, X.; Gu, C.; Gao, Z.; Cao, W.; Zheng, J. 5-Aminolevulinic acid-mediated sonodynamic therapy reverses macrophage and dendritic cell passivity in murine melanoma xenografts. Ultrasound Med. Biol. 2014, 40, 2125–2133. [Google Scholar] [CrossRef] [PubMed]
  26. Liu, F.; Hu, Z.; Qiu, L.; Hui, C.; Li, C.; Zhong, P.; Zhang, J. Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. J. Transl. Med. 2010, 8, 7. [Google Scholar] [CrossRef]
  27. Kennedy, J.E. High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 2005, 5, 321–327. [Google Scholar] [CrossRef]
  28. Williams, A.R. Disorganization and Disruption of Mammalian and Amoeboid Cells by Acoustic Microstreaming. J. Acoust. Soc. Am. 1972, 52, 688–693. [Google Scholar] [CrossRef]
  29. Haar, G.T.; Coussios, C. High intensity focused ultrasound: Physical principles and devices. Int. J. Hyperth. 2007, 23, 89–104. [Google Scholar] [CrossRef]
  30. Lauterborn, W.; Kurz, T.; Geisler, R.; Schanz, D.; Lindau, O. Acoustic cavitation, bubble dynamics and sonoluminescence. Ultrason. Sonochem. 2007, 14, 484–491. [Google Scholar] [CrossRef]
  31. Rengeng, L.; Qianyu, Z.; Yuehong, L.; Zhongzhong, P.; Libo, L. Sonodynamic therapy, a treatment developing from photodynamic therapy. Photodiagnosis Photodyn. Ther. 2017, 19, 159–166. [Google Scholar] [CrossRef]
  32. Pecha, R.; Gompf, B. Microimplosions: Cavitation collapse and shock wave emission on a nanosecond time scale. Phys. Rev. Lett. 2000, 84, 1328–1330. [Google Scholar] [CrossRef]
  33. Leighton, T. The Acoustic Bubble; Academic Press: Cambridge, MA, USA, 2012. [Google Scholar]
  34. Rooney, J.A. Hemolysis near an ultrasonically pulsating gas bubble. Science 1970, 169, 869–871. [Google Scholar] [CrossRef]
  35. Rosenthal, I.; Sostaric, J.Z.; Riesz, P. Sonodynamic therapy--a review of the synergistic effects of drugs and ultrasound. Ultrason. Sonochemistry 2004, 11, 349–363. [Google Scholar] [CrossRef] [PubMed]
  36. Yildirim, A.; Chattaraj, R.; Blum, N.T.; Goldscheitter, G.M.; Goodwin, A.P. Stable Encapsulation of Air in Mesoporous Silica Nanoparticles: Fluorocarbon-Free Nanoscale Ultrasound Contrast Agents. Adv. Healthc. Mater. 2016, 5, 1290–1298. [Google Scholar] [CrossRef] [PubMed]
  37. Brazzale, C.; Canaparo, R.; Racca, L.; Foglietta, F.; Durando, G.; Fantozzi, R.; Caliceti, P.; Salmaso, S.; Serpe, L. Enhanced selective sonosensitizing efficacy of ultrasound-based anticancer treatment by targeted gold nanoparticles. Nanomedicine 2016, 11, 3053–3070. [Google Scholar] [CrossRef] [PubMed]
  38. Suslick, K.S.; Doktycz, S.J.; Flint, E.B. On the origin of sonoluminescence and sonochemistry. Ultrasonics 1990, 28, 280–290. [Google Scholar] [CrossRef]
  39. Yin, H.; Chang, N.; Xu, S.; Wan, M. Sonoluminescence characterization of inertial cavitation inside a BSA phantom treated by pulsed HIFU. Ultrason. Sonochem. 2016, 32, 158–164. [Google Scholar] [CrossRef] [PubMed]
  40. Kessel, D.; Jeffers, R.; Fowlkes, J.B.; Cain, C. Porphyrin-induced enhancement of ultrasound cytotoxicity. Int. J. Radiat. Biol. 1994, 66, 221–228. [Google Scholar] [CrossRef] [PubMed]
  41. Misík, V.; Riesz, P. Free radical intermediates in sonodynamic therapy. Ann. N. Y. Acad. Sci. 2000, 899, 335–348. [Google Scholar] [CrossRef]
  42. Warner, S. Diagnostics + therapy = theranostics: Strategy requires teamwork, partnering, and tricky regulatory maneuvering. Scientist 2004, 18, 38–40. [Google Scholar]
  43. Ke, H.; Wang, J.; Dai, Z.; Jin, Y.; Qu, E.; Xing, Z.; Guo, C.; Yue, X.; Liu, J. Gold-nanoshelled microcapsules: A theranostic agent for ultrasound contrast imaging and photothermal therapy. Angew. Chem. 2011, 50, 3017–3021. [Google Scholar] [CrossRef] [PubMed]
  44. Gong, F.; Cheng, L.; Yang, N.; Betzer, O.; Feng, L.; Zhou, Q.; Li, Y.; Chen, R.; Popovtzer, R.; Liu, Z. Ultrasmall Oxygen-Deficient Bimetallic Oxide MnWOX Nanoparticles for Depletion of Endogenous GSH and Enhanced Sonodynamic Cancer Therapy. Adv. Mater. 2019, 31, e1900730. [Google Scholar] [CrossRef] [PubMed]
  45. Ho, Y.J.; Wu, C.H.; Jin, Q.F.; Lin, C.Y.; Chiang, P.H.; Wu, N.; Fan, C.H.; Yang, C.M.; Yeh, C.K. Superhydrophobic drug-loaded mesoporous silica nanoparticles capped with β-cyclodextrin for ultrasound image-guided combined antivascular and chemo-sonodynamic therapy. Biomaterials 2020, 232, 119723. [Google Scholar] [CrossRef]
  46. Li, Y.; Hao, L.; Liu, F.; Yin, L.; Yan, S.; Zhao, H.; Ding, X.; Guo, Y.; Cao, Y.; Li, P.; et al. Cell penetrating peptide-modified nanoparticles for tumor targeted imaging and synergistic effect of sonodynamic/HIFU therapy. Int. J. Nanomed. 2019, 14, 5875–5894. [Google Scholar] [CrossRef]
  47. Zhang, L.; Yi, H.; Song, J.; Huang, J.; Yang, K.; Tan, B.; Wang, D.; Yang, N.; Wang, Z.; Li, X. Mitochondria-Targeted and Ultrasound-Activated Nanodroplets for Enhanced Deep-Penetration Sonodynamic Cancer Therapy. ACS Appl. Mater. Interfaces 2019, 11, 9355–9366. [Google Scholar] [CrossRef]
  48. Cheng, K.; Zhang, R.Y.; Yang, X.Q.; Zhang, X.S.; Zhang, F.; An, J.; Wang, Z.Y.; Dong, Y.; Liu, B.; Zhao, Y.D.; et al. One-for-All Nanoplatform for Synergistic Mild Cascade-Potentiated Ultrasound Therapy Induced with Targeting Imaging-Guided Photothermal Therapy. ACS Appl. Mater. Interfaces 2020, 12, 40052–40066. [Google Scholar] [CrossRef]
  49. Chen, M.; Liang, X.; Gao, C.; Zhao, R.; Zhang, N.; Wang, S.; Chen, W.; Zhao, B.; Wang, J.; Dai, Z. Ultrasound Triggered Conversion of Porphyrin/Camptothecin-Fluoroxyuridine Triad Microbubbles into Nanoparticles Overcomes Multidrug Resistance in Colorectal Cancer. ACS Nano 2018, 12, 7312–7326. [Google Scholar] [CrossRef]
  50. Nomikou, N.; Curtis, K.; McEwan, C.; O’Hagan, B.M.G.; Callan, B.; Callan, J.F.; McHale, A.P. A versatile, stimulus-responsive nanoparticle-based platform for use in both sonodynamic and photodynamic cancer therapy. Acta Biomater. 2017, 49, 414–421. [Google Scholar] [CrossRef] [PubMed]
  51. Cao, Y.; Wu, T.; Dai, W.; Dong, H.; Zhang, X. TiO2 Nanosheets with the Au Nanocrystal-Decorated Edge for Mitochondria-Targeting Enhanced Sonodynamic Therapy. Chem. Mater. 2019, 31, 9105–9114. [Google Scholar] [CrossRef]
  52. Zheng, Y.; Liu, Y.; Wei, F.; Xiao, H.; Mou, J.; Wu, H.; Yang, S. Functionalized g-C3N4 nanosheets for potential use in magnetic resonance imaging-guided sonodynamic and nitric oxide combination therapy. Acta Biomater. 2021, 121, 592–604. [Google Scholar] [CrossRef]
  53. Wang, C.; Tian, Y.; Wu, B.; Cheng, W. Recent Progress Toward Imaging Application of Multifunction Sonosensitizers in Sonodynamic Therapy. Int. J. Nanomed. 2022, 17, 3511–3529. [Google Scholar] [CrossRef]
  54. Xu, C.; Huang, J.; Jiang, Y.; He, S.; Zhang, C.; Pu, K. Nanoparticles with ultrasound-induced afterglow luminescence for tumour-specific theranostics. Nat. Biomed. Eng. 2023, 7, 298–312. [Google Scholar] [CrossRef]
  55. Dong, C.; Jiang, Q.; Qian, X.; Wu, W.; Wang, W.; Yu, L.; Chen, Y. A self-assembled carrier-free nanosonosensitizer for photoacoustic imaging-guided synergistic chemo-sonodynamic cancer therapy. Nanoscale 2020, 12, 5587–5600. [Google Scholar] [CrossRef]
  56. Slagle, C.J.; Thamm, D.H.; Randall, E.K.; Borden, M.A. Click Conjugation of Cloaked Peptide Ligands to Microbubbles. Bioconjugate Chem. 2018, 29, 1534–1543. [Google Scholar] [CrossRef]
  57. Wang, Y.; Cong, H.; Wang, S.; Yu, B.; Shen, Y. Development and application of ultrasound contrast agents in biomedicine. J. Mater. Chem. B 2021, 9, 7633–7661. [Google Scholar] [CrossRef] [PubMed]
  58. Kloth, C.; Kratzer, W.; Schmidberger, J.; Beer, M.; Clevert, D.A.; Graeter, T. Ultrasound 2020—Diagnostics & Therapy: On the Way to Multimodal Ultrasound: Contrast-Enhanced Ultrasound (CEUS), Microvascular Doppler Techniques, Fusion Imaging, Sonoelastography, Interventional Sonography. In RöFo-Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgebenden Verfahren; Georg Thieme Verlag KG: Leipzig, Germany, 2021; Volume 193, pp. 23–32. [Google Scholar] [CrossRef]
  59. Claudon, M.; Dietrich, C.F.; Choi, B.I.; Cosgrove, D.O.; Kudo, M.; Nolsøe, C.P.; Piscaglia, F.; Wilson, S.R.; Barr, R.G.; Chammas, M.C.; et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver—Update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med. Biol. 2013, 39, 187–210. [Google Scholar] [CrossRef]
  60. Huynh, E.; Rajora, M.A.; Zheng, G. Multimodal micro, nano, and size conversion ultrasound agents for imaging and therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016, 8, 796–813. [Google Scholar] [CrossRef]
  61. Sun, S.; Xu, Y.; Fu, P.; Chen, M.; Sun, S.; Zhao, R.; Wang, J.; Liang, X.; Wang, S. Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA. Nanoscale 2018, 10, 19945–19956. [Google Scholar] [CrossRef] [PubMed]
  62. Lin, X.; Qiu, Y.; Song, L.; Chen, S.; Chen, X.; Huang, G.; Song, J.; Chen, X.; Yang, H. Ultrasound activation of liposomes for enhanced ultrasound imaging and synergistic gas and sonodynamic cancer therapy. Nanoscale Horiz. 2019, 4, 747–756. [Google Scholar] [CrossRef]
  63. He, Y.; Wan, J.; Yang, Y.; Yuan, P.; Yang, C.; Wang, Z.; Zhang, L. Multifunctional Polypyrrole-Coated Mesoporous TiO2 Nanocomposites for Photothermal, Sonodynamic, and Chemotherapeutic Treatments and Dual-Modal Ultrasound/Photoacoustic Imaging of Tumors. Adv. Healthc. Mater. 2019, 8, e1801254. [Google Scholar] [CrossRef]
  64. Zheng, J.; Sun, J.; Chen, J.; Zhu, S.; Chen, S.; Liu, Y.; Hao, L.; Wang, Z.; Chang, S. Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer. J. Control. Release 2021, 332, 448–459. [Google Scholar] [CrossRef] [PubMed]
  65. Feng, Q.; Li, Y.; Yang, X.; Zhang, W.; Hao, Y.; Zhang, H.; Hou, L.; Zhang, Z. Hypoxia-specific therapeutic agents delivery nanotheranostics: A sequential strategy for ultrasound mediated on-demand tritherapies and imaging of cancer. J. Control. Release 2018, 275, 192–200. [Google Scholar] [CrossRef] [PubMed]
  66. Zhang, T.; Zheng, Q.; Xie, C.; Fan, G.; Wang, Y.; Wu, Y.; Fu, Y.; Huang, J.; Craig, D.Q.M.; Cai, X.; et al. Integration of Silica Nanorattles with Manganese-Doped In2S3/InOOH to Enable Ultrasound-Mediated Tumor Theranostics. ACS Appl. Mater. Interfaces 2023, 15, 4883–4894. [Google Scholar] [CrossRef] [PubMed]
  67. Qin, Q.; Zhou, Y.; Li, P.; Liu, Y.; Deng, R.; Tang, R.; Wu, N.; Wan, L.; Ye, M.; Zhou, H.; et al. Phase-transition nanodroplets with immunomodulatory capabilities for potentiating mild magnetic hyperthermia to inhibit tumour proliferation and metastasis. J. Nanobiotechnol. 2023, 21, 131. [Google Scholar] [CrossRef]
  68. Liu, F.; Chen, Y.; Li, Y.; Guo, Y.; Cao, Y.; Li, P.; Wang, Z.; Gong, Y.; Ran, H. Folate-receptor-targeted laser-activable poly(lactide-co-glycolic acid) nanoparticles loaded with paclitaxel/indocyanine green for photoacoustic/ultrasound imaging and chemo/photothermal therapy. Int. J. Nanomed. 2018, 13, 5139–5158. [Google Scholar] [CrossRef]
  69. Zhang, H.; Chen, J.; Zhu, X.; Ren, Y.; Cao, F.; Zhu, L.; Hou, L.; Zhang, H.; Zhang, Z. Ultrasound induced phase-transition and invisible nanobomb for imaging-guided tumor sonodynamic therapy. J. Mater. Chem. B 2018, 6, 6108–6121. [Google Scholar] [CrossRef]
  70. Zhang, Q.; Wang, W.; Shen, H.; Tao, H.; Wu, Y.; Ma, L.; Yang, G.; Chang, R.; Wang, J.; Zhang, H.; et al. Low-Intensity Focused Ultrasound-Augmented Multifunctional Nanoparticles for Integrating Ultrasound Imaging and Synergistic Therapy of Metastatic Breast Cancer. Nanoscale Res. Lett. 2021, 16, 73. [Google Scholar] [CrossRef]
  71. Kang, Z.; Yang, M.; Feng, X.; Liao, H.; Zhang, Z.; Du, Y. Multifunctional Theranostic Nanoparticles for Enhanced Tumor Targeted Imaging and Synergistic FUS/Chemotherapy on Murine 4T1 Breast Cancer Cell. Int. J. Nanomed. 2022, 17, 2165–2187. [Google Scholar] [CrossRef]
  72. Hou, R.; Liang, X.; Li, X.; Zhang, X.; Ma, X.; Wang, F. In situ conversion of rose bengal microbubbles into nanoparticles for ultrasound imaging guided sonodynamic therapy with enhanced antitumor efficacy. Biomater. Sci. 2020, 8, 2526–2536. [Google Scholar] [CrossRef]
  73. Jiang, Z.; Zhang, M.; Li, P.; Wang, Y.; Fu, Q. Nanomaterial-based CT contrast agents and their applications in image-guided therapy. Theranostics 2023, 13, 483–509. [Google Scholar] [CrossRef]
  74. Pan, X.; Siewerdsen, J.; La Riviere, P.J.; Kalender, W.A. Anniversary paper. Development of x-ray computed tomography: The role of medical physics and AAPM from the 1970s to present. Med. Phys. 2008, 35, 3728–3739. [Google Scholar] [CrossRef]
  75. Zhang, R.Y.; Cheng, K.; Xuan, Y.; Yang, X.Q.; An, J.; Hu, Y.G.; Liu, B.; Zhao, Y.D. A pH/ultrasonic dual-response step-targeting enterosoluble granule for combined sonodynamic-chemotherapy guided via gastrointestinal tract imaging in orthotopic colorectal cancer. Nanoscale 2021, 13, 4278–4294. [Google Scholar] [CrossRef] [PubMed]
  76. Guo, L.; Xi, J.; Teng, J.; Wang, J.; Chen, Y. Magnetic Resonance Neuroimaging Contrast Agents of Nanomaterials. Biomed. Res. Int. 2022, 2022, 6790665. [Google Scholar] [CrossRef] [PubMed]
  77. Yuan, P.; Song, D. MRI tracing non-invasive TiO2-based nanoparticles activated by ultrasound for multi-mechanism therapy of prostatic cancer. Nanotechnology 2018, 29, 125101. [Google Scholar] [CrossRef] [PubMed]
  78. Geng, P.; Yu, N.; Liu, X.; Zhu, Q.; Wen, M.; Ren, Q.; Qiu, P.; Zhang, H.; Li, M.; Chen, Z. Sub 5 nm Gd3+-Hemoporfin Framework Nanodots for Augmented Sonodynamic Theranostics and Fast Renal Clearance. Adv. Healthc. Mater. 2021, 10, e2100703. [Google Scholar] [CrossRef]
  79. Geethanath, S.; Vaughan, J.T., Jr. Accessible magnetic resonance imaging: A review. J. Magn. Reson. Imaging 2019, 49, e65–e77. [Google Scholar] [CrossRef]
  80. Pellico, J.; Ellis, C.M.; Davis, J.J. Nanoparticle-Based Paramagnetic Contrast Agents for Magnetic Resonance Imaging. Contrast Media Mol. Imaging 2019, 2019, 1845637. [Google Scholar] [CrossRef]
  81. De León-Rodríguez, L.M.; Martins, A.F.; Pinho, M.C.; Rofsky, N.M.; Sherry, A.D. Basic MR relaxation mechanisms and contrast agent design. J. Magn. Reson. Imaging 2015, 42, 545–565. [Google Scholar] [CrossRef]
  82. Abd-Ellah, M.K.; Awad, A.I.; Khalaf, A.A.M.; Hamed, H.F.A. A review on brain tumor diagnosis from MRI images: Practical implications, key achievements, and lessons learned. Magn. Reson. Imaging 2019, 61, 300–318. [Google Scholar] [CrossRef]
  83. Lei, H.; Wang, X.; Bai, S.; Gong, F.; Yang, N.; Gong, Y.; Hou, L.; Cao, M.; Liu, Z.; Cheng, L. Biodegradable Fe-Doped Vanadium Disulfide Theranostic Nanosheets for Enhanced Sonodynamic/Chemodynamic Therapy. ACS Appl. Mater. Interfaces 2020, 12, 52370–52382. [Google Scholar] [CrossRef]
  84. Wang, Z.; Liu, B.; Sun, Q.; Feng, L.; He, F.; Yang, P.; Gai, S.; Quan, Z.; Lin, J. Upconverted Metal-Organic Framework Janus Architecture for Near-Infrared and Ultrasound Co-Enhanced High Performance Tumor Therapy. ACS Nano 2021, 15, 12342–12357. [Google Scholar] [CrossRef]
  85. Bai, S.; Yang, N.; Wang, X.; Gong, F.; Dong, Z.; Gong, Y.; Liu, Z.; Cheng, L. Ultrasmall Iron-Doped Titanium Oxide Nanodots for Enhanced Sonodynamic and Chemodynamic Cancer Therapy. ACS Nano 2020, 14, 15119–15130. [Google Scholar] [CrossRef] [PubMed]
  86. Jiang, F.; Yang, C.; Ding, B.; Liang, S.; Zhao, Y.; Cheng, Z.; Liu, M.; Xing, B.; Ma, P.; Lin, J. Tumor microenvironment-responsive MnSiO3-Pt@BSA-Ce6 nanoplatform for synergistic catalysis-enhanced sonodynamic and chemodynamic cancer therapy. Chin. Chem. Lett. 2022, 33, 2959–2964. [Google Scholar] [CrossRef]
  87. Wang, J.; Huang, J.; Zhou, W.; Zhao, J.; Peng, Q.; Zhang, L.; Wang, Z.; Li, P.; Li, R. Hypoxia modulation by dual-drug nanoparticles for enhanced synergistic sonodynamic and starvation therapy. J. Nanobiotechnol. 2021, 19, 87. [Google Scholar] [CrossRef]
  88. Liu, S.; Zhang, W.; Chen, Q.; Hou, J.; Wang, J.; Zhong, Y.; Wang, X.; Jiang, W.; Ran, H.; Guo, D. Multifunctional nanozyme for multimodal imaging-guided enhanced sonodynamic therapy by regulating the tumor microenvironment. Nanoscale 2021, 13, 14049–14066. [Google Scholar] [CrossRef]
  89. Du, B.; Yan, X.; Ding, X.; Wang, Q.; Du, Q.; Xu, T.; Shen, G.; Yao, H.; Zhou, J. Oxygen Self-Production Red Blood Cell Carrier System for MRI Mediated Cancer Therapy: Ferryl-Hb, Sonodynamic, and Chemical Therapy. ACS Biomater. Sci. Eng. 2018, 4, 4132–4143. [Google Scholar] [CrossRef]
  90. Wang, L.; Song, W.; Choi, S.; Yu, K.; Zhang, F.; Guo, W.; Ma, Y.; Wang, K.; Qu, F.; Lin, H. Hollow CoP@N-Carbon Nanospheres: Heterostructure and Glucose-Enhanced Charge Separation for Sonodynamic/Starvation Therapy. ACS Appl. Mater. Interfaces 2023, 15, 2552–2563. [Google Scholar] [CrossRef]
  91. Ma, A.; Chen, H.; Cui, Y.; Luo, Z.; Liang, R.; Wu, Z.; Chen, Z.; Yin, T.; Ni, J.; Zheng, M.; et al. Metalloporphyrin Complex-Based Nanosonosensitizers for Deep-Tissue Tumor Theranostics by Noninvasive Sonodynamic Therapy. Small 2019, 15, e1804028. [Google Scholar] [CrossRef] [PubMed]
  92. Guan, S.; Liu, X.; Li, C.; Wang, X.; Cao, D.; Wang, J.; Lin, L.; Lu, J.; Deng, G.; Hu, J. Intracellular Mutual Amplification of Oxidative Stress and Inhibition Multidrug Resistance for Enhanced Sonodynamic/Chemodynamic/Chemo Therapy. Small 2022, 18, e2107160. [Google Scholar] [CrossRef]
  93. Neuschmelting, V.; Harmsen, S.; Beziere, N.; Lockau, H.; Hsu, H.T.; Huang, R.; Razansky, D.; Ntziachristos, V.; Kircher, M.F. Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation. Small 2018, 14, e1800740. [Google Scholar] [CrossRef]
  94. Salvatori, M.; Rizzo, A.; Rovera, G.; Indovina, L.; Schillaci, O. Radiation dose in nuclear medicine: The hybrid imaging. Radiol. Med. 2019, 124, 768–776. [Google Scholar] [CrossRef] [PubMed]
  95. Perry, J.L.; Mason, K.; Sutton, B.P.; Kuehn, D.P. Can Dynamic MRI Be Used to Accurately Identify Velopharyngeal Closure Patterns? Cleft Palate-Craniofacial J. 2018, 55, 499–507. [Google Scholar] [CrossRef] [PubMed]
  96. Guo, W.; Chen, Z.; Tan, L.; Gu, D.; Ren, X.; Fu, C.; Wu, Q.; Meng, X. Emerging biocompatible nanoplatforms for the potential application in diagnosis and therapy of deep tumors. View 2021, 3, 20200174. [Google Scholar] [CrossRef]
  97. Jennings, L.E.; Long, N.J. ‘Two is better than one’--probes for dual-modality molecular imaging. Chem. Commun. 2009, 24, 3511–3524. [Google Scholar] [CrossRef] [PubMed]
  98. Lee, S.Y.; Jeon, S.I.; Jung, S.; Chung, I.J.; Ahn, C.H. Targeted multimodal imaging modalities. Adv. Drug Deliv. Rev. 2014, 76, 60–78. [Google Scholar] [CrossRef]
  99. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med. 2008, 49 (Suppl. 2), 113s–128s. [Google Scholar] [CrossRef]
Molecules 28 06484 g001
Figure 1. Principles of SDT for oncology treatment. (A) Ultrasound carries acoustic energy that can produce both thermal and non-thermal effects in the tumor region. The thermal effect can directly cause cellular damage. Non-thermal effects mainly occur as cavitation effects. (B) ROS generation. Ultrasound induces intracellular ROS generation inside the tumor by producing cavitation effects and activating sonosensitizers. (C) ROS cause tumor cell death by inducing cellular autophagy and necrosis, among other pathways. Created with BioRender.com (accessed on 23 August 2023).
Figure 1. Principles of SDT for oncology treatment. (A) Ultrasound carries acoustic energy that can produce both thermal and non-thermal effects in the tumor region. The thermal effect can directly cause cellular damage. Non-thermal effects mainly occur as cavitation effects. (B) ROS generation. Ultrasound induces intracellular ROS generation inside the tumor by producing cavitation effects and activating sonosensitizers. (C) ROS cause tumor cell death by inducing cellular autophagy and necrosis, among other pathways. Created with BioRender.com (accessed on 23 August 2023).
Molecules 28 06484 g001
Molecules 28 06484 g002
Figure 2. Summary of the integrated diagnosis and treatment scheme involving sonodynamic therapy. MRI: magnetic resonance imaging. CEUS: Contrast-Enhanced Ultrasound. Fluorescence imaging includes FL microscopy images [47] and near infra-red (nIR) fluorescence imaging [50]. IR: infrared image [53]. Afterglow luminescence image [54]. Mult-Mode image contains Dual-mode and Triple-mode. PA: Photoacoustic imaging [55]. Created with BioRender.com (accessed on 23 August 2023).
Figure 2. Summary of the integrated diagnosis and treatment scheme involving sonodynamic therapy. MRI: magnetic resonance imaging. CEUS: Contrast-Enhanced Ultrasound. Fluorescence imaging includes FL microscopy images [47] and near infra-red (nIR) fluorescence imaging [50]. IR: infrared image [53]. Afterglow luminescence image [54]. Mult-Mode image contains Dual-mode and Triple-mode. PA: Photoacoustic imaging [55]. Created with BioRender.com (accessed on 23 August 2023).
Molecules 28 06484 g002
Molecules 28 06484 g003
Figure 3. (A) Grayscale and color US images (B mode and Harmonic mode) of TRAMP cells implanted in the tumor before (left) and after (right) injection of PCF-MBs. The red arrows highlight the tumor sites. (B) In vivo B-mode US imaging. (4T1 tumor-bearing nude mice). (C) Corresponding grayscale values of tumors obtained 5 min after intratumoral injection of PBS, SiO2 (10 mg/kg), MISO (5 mg/kg), and SMISO (15 mg/kg) (* p < 0.05, ** p < 0.01, n = 3, mean ± SD). Scale bar: 2 mm. (D) Before and after comparison of B-mode and CEUS-mode imaging with ultrasound irradiation. Notes: (A) Adapted with permission from Ref. [49]. Copyright 2018, American Chemical Society. (B,C) Adapted with permission from Ref. [66]. Copyright 2023, American Chemical Society. (D) Adapted with permission from Ref. [47]. Copyright 2019, American Chemical Society.
Figure 3. (A) Grayscale and color US images (B mode and Harmonic mode) of TRAMP cells implanted in the tumor before (left) and after (right) injection of PCF-MBs. The red arrows highlight the tumor sites. (B) In vivo B-mode US imaging. (4T1 tumor-bearing nude mice). (C) Corresponding grayscale values of tumors obtained 5 min after intratumoral injection of PBS, SiO2 (10 mg/kg), MISO (5 mg/kg), and SMISO (15 mg/kg) (* p < 0.05, ** p < 0.01, n = 3, mean ± SD). Scale bar: 2 mm. (D) Before and after comparison of B-mode and CEUS-mode imaging with ultrasound irradiation. Notes: (A) Adapted with permission from Ref. [49]. Copyright 2018, American Chemical Society. (B,C) Adapted with permission from Ref. [66]. Copyright 2023, American Chemical Society. (D) Adapted with permission from Ref. [47]. Copyright 2019, American Chemical Society.
Molecules 28 06484 g003
Molecules 28 06484 g004
Figure 4. (A) The process of synthesis of Au-TiO2-A-TPP. (B) Comparison of CT images of mice before and after intravenous injection of Au-TiO2-A-TPP (10 mg/kg). The red circles highlight the tumor sites. (C) In vitro CT imaging and CT signal values about different concentrations of Au-TiO2-A-TPP. (D) Blood circulation time in MCF-7 tumor-bearing mice after intravenous injection of Au-TiO2-A-TPP (10 mg/kg). (E) CT imaging of HeLa tumor-bearing mice after in vivo injection of ABS-FA and ABS; red dashed circle: tumor sites. (F) Low power (0.35 W/cm2) infrared thermograms of tumor-bearing mice taken at different time points. The white arrows highlight the tumor sites. Notes: (A–D) Adapted with permission from Ref. [51]. Copyright 2019, American Chemical Society. (E,F) Adapted with permission from Ref. [48]. Copyright 2020, American Chemical Society.
Figure 4. (A) The process of synthesis of Au-TiO2-A-TPP. (B) Comparison of CT images of mice before and after intravenous injection of Au-TiO2-A-TPP (10 mg/kg). The red circles highlight the tumor sites. (C) In vitro CT imaging and CT signal values about different concentrations of Au-TiO2-A-TPP. (D) Blood circulation time in MCF-7 tumor-bearing mice after intravenous injection of Au-TiO2-A-TPP (10 mg/kg). (E) CT imaging of HeLa tumor-bearing mice after in vivo injection of ABS-FA and ABS; red dashed circle: tumor sites. (F) Low power (0.35 W/cm2) infrared thermograms of tumor-bearing mice taken at different time points. The white arrows highlight the tumor sites. Notes: (A–D) Adapted with permission from Ref. [51]. Copyright 2019, American Chemical Society. (E,F) Adapted with permission from Ref. [48]. Copyright 2020, American Chemical Society.
Molecules 28 06484 g004
Molecules 28 06484 g005
Figure 5. (A) Schematic diagram of the synthesis of Fe-VS2 NSs. (B) Comparative T1-weighted MR grayscale images of 4T1 tumor-bearing mice before and after intravenous injection of Fe-VS2-PEG NSs. The red circles highlight the tumor sites. (C) Qualitative analysis of MR intensity showed in B. (D) T1-weighted magnetic resonance image and r1 of Fe-VS2-PEG solutions at different molar concentrations of V. (E) In vivo T2-MRI of tumor-bearing mice by intravenous injection of UPF or UPFB at different time intervals. Mice were imaged on a 1.2 T MRI scanner (Shanghai, China) for different periods. Tumor sites are marked with red ellipses. (F) Biodistribution of Zr (% injected dose (ID) of Zr per gram of tissues) in major tissues and tumors at different times after injection of UPFB. (H) Fe (% injected dose (ID) of Fe per gram of tissues) content in major tissues and tumors at different times after UPFB injection. (G) Blood circulation profile after intravenous injection of UPFB (n = 5). The half-time (t1/2) was calculated to be ≈3.381 h. (I) T1 relaxation rate (1/T1) of mZMD NCs measured using the concentration of Mn2+ (inset: MR images of different concentrations of mZMD NCs in PBS (pH 6.5). Notes: (A–D) Adapted with permission from Ref. [83]. Copyright 2020, American Chemical Society. (E–H) Adapted with permission from Ref. [84]. Copyright 2021, American Chemical Society. (I) Adapted with permission from Ref. [91]. Copyright 2022 Wiley-VCH GmbH.
Figure 5. (A) Schematic diagram of the synthesis of Fe-VS2 NSs. (B) Comparative T1-weighted MR grayscale images of 4T1 tumor-bearing mice before and after intravenous injection of Fe-VS2-PEG NSs. The red circles highlight the tumor sites. (C) Qualitative analysis of MR intensity showed in B. (D) T1-weighted magnetic resonance image and r1 of Fe-VS2-PEG solutions at different molar concentrations of V. (E) In vivo T2-MRI of tumor-bearing mice by intravenous injection of UPF or UPFB at different time intervals. Mice were imaged on a 1.2 T MRI scanner (Shanghai, China) for different periods. Tumor sites are marked with red ellipses. (F) Biodistribution of Zr (% injected dose (ID) of Zr per gram of tissues) in major tissues and tumors at different times after injection of UPFB. (H) Fe (% injected dose (ID) of Fe per gram of tissues) content in major tissues and tumors at different times after UPFB injection. (G) Blood circulation profile after intravenous injection of UPFB (n = 5). The half-time (t1/2) was calculated to be ≈3.381 h. (I) T1 relaxation rate (1/T1) of mZMD NCs measured using the concentration of Mn2+ (inset: MR images of different concentrations of mZMD NCs in PBS (pH 6.5). Notes: (A–D) Adapted with permission from Ref. [83]. Copyright 2020, American Chemical Society. (E–H) Adapted with permission from Ref. [84]. Copyright 2021, American Chemical Society. (I) Adapted with permission from Ref. [91]. Copyright 2022 Wiley-VCH GmbH.
Molecules 28 06484 g005
Table 1. US Imaging Characteristics of the Multifunctional Sonosensitizers.
Table 1. US Imaging Characteristics of the Multifunctional Sonosensitizers.
SonosensitizersProbesBiological ModelSDT ResultImaging EffectRef.
Molecules 28 06484 i001
PCF-MBs		PCFHT-29 cancer-bearing Balb/c
nude mice		tumor
inhibition rate of more than 50%		20 s post-injection,
the US imaging signal reached the maximum; and the contrast
enhancement could last for more than 3 min		[49]
Molecules 28 06484 i002
FMSN-DOX		FMSNsTRAMP
tumor-bearing nude mice		The gradual reduction in tumor growthfrom day 1 to day 9 with significant contrast enhancement within the tumor.[45]
Molecules 28 06484 i003
HMME/MCC-HA		MCC NPsMCF-7 tumor-bearing nude micesuccessfully suppressed the tumor volume
with the V/V0 of 0.87 ± 0.13		strong US signals in tumor site at 3 h post-injection,
and particularly after exposure to US stimulus		[8]
Molecules 28 06484 i004
Lip-AIPH		AIPHMCF-7 tumor-bearing micea highly significant antitumor effect was achieved in
mice in the group of Lip-AIPH with US irradiation		a highly significant antitumor effect was achieved in
mice in the group of Lip-AIPH with US irradiation		[62]
Molecules 28 06484 i005
mTiO2@PPY-HNK		mTiO24T1 tumor modelsignificantly inhibit the tumor growthas the concentration increases, the ultrasound signal is more intense and the image is clearer[63]
Molecules 28 06484 i006
OIX_NPs		PFPID8
cells into the left shoulder (the primary tumor)		significant inhibition of tumor volumepeaking at 4 h post-injection.[64]
Molecules 28 06484 i007
TPZ/HMTNPs-SNO		HMTNPs-SNOMCF-7 tumor-bearing nude miceexhibited an effective therapeutic
effect		compared with the saline group, showed local enhancement at the tumor site.[65]
Molecules 28 06484 i008
IR780-NDs		PFPbreast cancer 4T1 nude miceTumor weight drop24 h after the injection of IR780-NDs a bright US signal occurred at the
tumor site.		[47]
Molecules 28 06484 i009
SMISO NPs		SMISO4T1 tumor-bearing nude micethe
inhibition rate of tumor growth in the SMISO + US group
reached 88.2%		the grayscale values of US images increase with them.
concentration increases		[66]
Molecules 28 06484 i010
RPPs&SPIOs		RPPs4T1 tumorsa 100% survival rate of mice at 90 daysShift in RPPs after thermal stimulation results in significant contrast enhancement[67]
Molecules 28 06484 i011
FA-PEG-PLGA-Ptx@ICG-Pfh NPs		PfhMDA-MB231 tumor-bearing micetumor growth was significantly inhibitedimages were greatly improved[68]
Molecules 28 06484 i012
RBC-HPBs/HMME/PFH		PFH4T1 tumor-bearing female
mice		enhancing tumor treatment effects of HMMEA clear US signal was observed at 4 h after injection, and the strongest signal appeared at 8 h.[69]
Molecules 28 06484 i013
Ce6-PFP-DTX/PLGA		PFPbreast cancer 4T1 nude micemuch higher inhibition rate of the CPDP NPs + LIFU groupafter LIFU irradiation, the corresponding intensity
of CPDP NPs was elevated compared with the
pre-irradiation group		[70]
Molecules 28 06484 i014
AS1411-DOX-PFH-PEG@PLGA		PFHbreast cancer 4T1 nude micethe tumor volumes significantly decreasedIncreased imaging ability of ADPPs in vivo within 24 h after intravenous injection[71]
Molecules 28 06484 i015
RB-MBs		MBsHT-29 tumor mouse
model		-a contrast-enhanced ultrasound imaging mode at a frequency of 5 MHz[72]
Table 2. CT Imaging Characteristics of the Multifunctional Sonosensitizers.
Table 2. CT Imaging Characteristics of the Multifunctional Sonosensitizers.
SonosensitizersProbesBiological ModelTreatment ResultImaging EffectRef.
Molecules 28 06484 i016
MnWOX-PEG		W(CO)64T1 tumor-bearing miceTumor weight dropCT imaging signal intensity was almost 2.4 times higher than that of the control group[44]
Molecules 28 06484 i017
AgBiS2@DSPE-PEG2000-FA		AgBiS2HeLa tumor-bearing miceTumor size dropThe CT signal intensity at the tumor site gradually increased and peaked at 6h after the injection[48]
Molecules 28 06484 i018
Au-TiO2-A-TPP		Au-TiO2MCF-7 tumor-bearing miceTumor weight dropThe CT signal in the tumor area reached its maximum at 24 h[51]
Molecules 28 06484 i019
GMCDS-FA@CMC		Au@mSiO2orthotopic colorectal tumorDecreased number and smaller diameter of colorectal tumorsThe nanoprobe remained in the colorectal
region		[75]
Table 3. MR Imaging Characteristics of the Multifunctional Sonosensitizers.
Table 3. MR Imaging Characteristics of the Multifunctional Sonosensitizers.
SonosensitizersProbesBiological ModelSDT ResultImaging EffectRef.
Molecules 28 06484 i020
UPFB		MOFs (Fe3+)U14 tumor-bearing Kunming miceincreased inhibition of tumor growthenhanced T2 contrast signal[84]
Molecules 28 06484 i021
Fe-TiO2 NDs		Fe3+4T1 tumor-bearing micebetter
tumor inhibition		The brightening effect through the T1-weighted MR images[85]
Molecules 28 06484 i022
Fe-VS2-PEG		Fe3+4T1 cells
subcutaneously in BALB/c mice		better treatment
effect and a longer survival period		the tumor had an obvious brightening effect 24 h after i.v. injection (T1)[83]
Molecules 28 06484 i023
OCN-PEG-(Ce6-Gd3+)/BNN6		Ga3+4T1 tumor-bearing micethe tumor suppression rate reached 63.2%The T1-weighted contrast effect was significantly enhanced[52]
Molecules 28 06484 i024
MnSiO3-Pt@BSA-Ce6(MPBC)		Mn2+U14 tumor-bearing Balb/c micetumor growth inhibitionthe T1−MR signal of the tumor enhanced[86]
Molecules 28 06484 i025
MG@P NPs		PMnC (Mn)4T1 tumor-bearing micethe tumor growth of
Mice remarkably suppressed		T1 signal of the tumor region showed an increasing trend within 24 h and then decreased[87]
Molecules 28 06484 i026
F3-PLGA@MB/Gd NPs		Gd-DTPA-BMAthe nude mice bearing MDA-MB-231 tumorsinduce tumor cell apoptosisLinear signal dependence of T1 intensity values[46]
Molecules 28 06484 i027
Ang-IR780-MnO2-PLGA (AIMP)		MnO2U87MG
tumor-bearing mice		enhanced SDT effectA linear relationship was shown between the 1/T1
values and Mn concentration		[88]
Molecules 28 06484 i028
DOX/Mn-TPPS@RBCS		Mn-TPPSMCF-7 tumor-bearing nude miceInhibit tumor growthT1-weighted MR imaging results in enhancement[89]
Molecules 28 06484 i029
MnTTP-HSA		MnTTP (Mn)MCF-7 tumor-bearing nude micethe best in completely inhibiting tumora T1
the positive signal at the tumor showed an increasing trend within
3 h and then gradually decreased		[90]
Molecules 28 06484 i030
mZMD		MnO2HeLa tumor xenograft-bearing nude micesignificant suppression
effects		the concentration of the NCs increased, the T1 MR images became brighter and brighter[91]
Molecules 28 06484 i031
GdHF-NDs		Ga3+CT26 tumor-bearing miceGdHF-NDs/PEG + US
shows the most potent efficiency in tumor suppression (73.7%)		T1 signal strength increased[78]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Liang, Y.; Zhang, M.; Zhang, Y.; Zhang, M. Ultrasound Sonosensitizers for Tumor Sonodynamic Therapy and Imaging: A New Direction with Clinical Translation. Molecules 2023, 28, 6484. https://doi.org/10.3390/molecules28186484

AMA Style

Liang Y, Zhang M, Zhang Y, Zhang M. Ultrasound Sonosensitizers for Tumor Sonodynamic Therapy and Imaging: A New Direction with Clinical Translation. Molecules. 2023; 28(18):6484. https://doi.org/10.3390/molecules28186484

Chicago/Turabian Style

Liang, Yunlong, Mingzhen Zhang, Yujie Zhang, and Mingxin Zhang. 2023. "Ultrasound Sonosensitizers for Tumor Sonodynamic Therapy and Imaging: A New Direction with Clinical Translation" Molecules 28, no. 18: 6484. https://doi.org/10.3390/molecules28186484

APA Style

Liang, Y., Zhang, M., Zhang, Y., & Zhang, M. (2023). Ultrasound Sonosensitizers for Tumor Sonodynamic Therapy and Imaging: A New Direction with Clinical Translation. Molecules, 28(18), 6484. https://doi.org/10.3390/molecules28186484

Article Metrics

Back to TopTop